

Supplementary Table 3. Differences in baseline characteristics between the patients with improvement and with non-improvement of NAFLD fibrosis score 6 months after IL-17i treatment in patients with MAFLD

	Non-improvement		Improvement		P-value
	Value	Range	Value	Range	
Age (years)	44.5 (38.5–52.8)	28.0–89.0	49.0 (41.0–54.0)	21.0–76.0	0.3540
Sex, female/male (%)	29.2/70.8 (7/17)	N/A	20.0/80.0 (7/28)	N/A	0.4162
Body mass index (kg/m ²)	26.0 (24.1–28.9)	21.2–44.6	27.7 (24.6–30.0)	19.9–38.1	0.4047
Subtype of psoriasis, PV/PsA/PE/PuP (%)	66.7/12.5/8.3/12.5 (16/3/2/3)	N/A	57.1/37.2/5.7/0.0 (20/13/2/0)	N/A	0.0477
Duration after the diagnosis of psoriasis (years)	15.5 (7.5–20.8)	1.5–43.0	11.0 (4.0–20.0)	0.5–36.0	0.2968
Experience of biological medication, biologic naïve/switching (%)	83.3/16.7 (20/4)	N/A	82.9/17.1 (29/6)	N/A	0.9618
PASI	11.3 (5.9–19.1)	1.5–30.8	8.7 (4.0–14.0)	1.2–33.8	0.2732
PASI, <5/5–9/≥10 (%)	12.5/33.3/54.2 (3/8/13)	N/A	34.3/17.1/48.6 (12/6/17)	N/A	0.1033
Type of IL-17 inhibitor, secukinumab/ixekizumab (%)	66.7/33.3 (16/8)	N/A	57.1/42.9 (20/15)	N/A	0.4612
Alcoholic intake, none/moderate/mild/heavy/no data (%)	50.0/0.0/0.0/4.2/45.8 (12/0/0/1/11)	N/A	40.0/5.7/8.6/0.0/45.7 (14/2/3/0/16)	N/A	0.2664
Obesity, presence/absence (%)	62.5/37.5 (15/9)	N/A	74.3/25.7 (26/9)	N/A	0.3341
Diabetes mellitus, presence/absence (%)	12.5/87.5 (3/21)	N/A	38.2/61.8 (13/21)	N/A	0.0308
Hypertension, presence/absence (%)	25.0/75.0 (6/18)	N/A	40.0/60.0 (14/21)	N/A	0.2318
Dyslipidemia, presence/absence (%)	12.5/87.5 (3/21)	N/A	14.3/85.7 (5/30)	N/A	0.8440
Red blood cell count (×10 ⁶ /μL)	4.95 (4.34–5.28)	3.80–5.94	4.94 (4.64–5.14)	3.90–5.53	1.0000
Hemoglobin (g/dL)	14.8 (12.9–15.4)	11.2–17.1	15.1 (14.4–15.5)	10.1–16.6	0.2167
White blood cell count (×10 ³ /μL)	5.9 (5.3–7.8)	4.1–9.0	6.7 (6.0–8.0)	4.1–9.4	0.1600
Platelet count (×10 ⁴ /μL)	25.4 (23.3–28.6)	16.3–35.6	25.0 (21.1–28.5)	14.6–43.1	0.4847
AST (U/L)	21.5 (18.0–35.3)	16.0–181.0	29.0 (23.0–39.0)	13.0–75.0	0.0719
ALT (U/L)	28.0 (12.3–45.8)	10.0–241.0	32.0 (23.0–56.0)	12.0–112.0	0.0650
ALP (U/L)	209.0 (156.0–258.0)	123.0–334.0	234.0 (194.0–264.0)	151.0–439.0	0.1853
GGT (U/L)	32.5 (22.5–63.8)	11.0–238.0	44.0 (24.0–70.0)	11.0–219.0	0.4521
Total bilirubin (mg/dL)	0.6 (0.5–0.8)	0.4–1.6	0.6 (0.5–0.9)	0.2–1.9	0.9214
Albumin (g/dL)	4.4 (4.2–4.6)	3.8–4.8	4.3 (4.2–4.6)	3.4–4.9	0.9752
HbA1c (%)	5.6 (5.3–6.7)	5.2–7.5	6.3 (5.8–7.9)	5.1–10.5	0.0223
Total cholesterol (mg/dL)	204.0 (185.0–218.0)	142.0–280.0	205.0 (182.0–228.0)	148.0–336.0	0.8452
HDL-cholesterol (mg/dL)	51.0 (47.0–60.0)	31.0–90.0	45.5 (39.0–55.0)	33.0–83.0	0.1035
LDL-cholesterol (mg/dL)	119.5 (90.0–131.0)	62.0–184.0	117.0 (91.5–128.5)	62.0–165.0	0.7177
Triglycerides (mg/dL)	152.0 (112.5–254.0)	69.0–896.0	190.5 (120.5–274.8)	52.0–1,649.0	0.4369
BUN (mg/dL)	12.0 (11.0–14.0)	9.0–23.0	14.0 (12.0–17.0)	8.0–26.0	0.0562
Creatinine (mg/dL)	0.83 (0.72–0.91)	0.56–1.12	0.83 (0.72–1.01)	0.44–1.80	0.8049

Values are presented as median (interquartile range) or range (minimum-maximum).

NAFLD, non-alcoholic fatty liver disease; IL-17i, interleukin-17 inhibitor; MAFLD, metabolic dysfunction-associated fatty liver disease; N/A, not applicable; PV, psoriasis vulgaris; PsA, psoriatic arthritis; PE, psoriatic erythroderma; PuP, pustular psoriasis; PASI, psoriasis area and severity index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BUN, blood urea nitrogen.